CureDuchenne Ventures, LLC 4
4 · Dyne Therapeutics, Inc. · Filed Sep 23, 2020
Insider Transaction Report
Form 4
CureDuchenne Ventures, LLC
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2020-09-21−2,000,000→ 0 total→ Common Stock (602,972 underlying) - Conversion
Common Stock
2020-09-21+602,972→ 602,972 total
Footnotes (1)
- [F1]On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.